NEW YORK – Seqster will work with drug development data aggregation startup Medable to integrate real-world genomic and phenotypic data for decentralized clinical trials, the companies announced Monday.
San Diego-based Seqster collects individuals' health data from wearables, consumer genetic testing, electronic health records, and social determinants of health, giving users the ability to explore it on their own or share it with others. They can contribute specific health data to research. Caregivers can use the platform to manage their loved ones' medical data in a single portal.
Medable, of Palo Alto, California, has built a cloud-based digital platform for designing and managing clinical trials and connecting patients, trial sites, and researchers.
Both companies also partner with Datavant to integrate deidentified patient data from multiple sources, including EHRs, claims records, diagnostics, wearables, and genomics.
"By shifting from outdated retrieval methods to real-time data streams, pharma and biotech companies can more quickly identify potential trial participants — and help them track and share health data at scale," Seqster CEO and Cofounder Ardy Arianpour said in a statement.
"Patients want clinical trials to fit into their real-world experience, not the other way around," added Medable CEO and Cofounder Michelle Longmire. "Working with Seqster, we can integrate more data sources and data streams to provide clinicians with a more holistic view of patient health, leading to higher-quality trial results while simplifying the patient experience."